Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Contact phone
Nurse - Tracy | 517.364.2835
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Gastrointestinal
Webform